Zavarsek S, Johnston RV; Health Technology Assessment International. Meeting (1st : 2004 : Krakow, Poland).
Proc One HTA Health Technol Assess Int Meet 1st 2004 Krakow Pol. 2004; 1: 269.
Monash Institute of Health Services Research, Melbourne, Victoria, Australia.
OBJECTIVES: To assess the effectiveness of PDT-V for subfoveal CNV to inform the Medical Services Advisory Committee (MSAC) in its decision to allocate public funding for new technologies. METHODS: Relevant articles were identified from a systematic literature review of electronic databases, HTA and other relevant websites to May 2003. RESULTS: Evidence of the effectiveness of PDT-V was available from RCTs for patients with subfoveal CNV secondary to age-related macular degeneration (AMD) and pathologic myopia (PM). In patients with CNV in AMD, PDT-V was more effective than placebo in reducing the rate of visual acuity loss in patients with predominantly classic lesions at 12 (RD=0.28; 95% CI 0.15, 0.41) and 24 (RD=0.28; 95% CI 0.15, 0.40) months and in patients with occult with no classic lesions at 24 (RD=0.14; 95% CI 0.02, 0.26), but not at 12 months. Meta-analysis was also performed. PDT-V was more effective than placebo in reducing visual acuity loss in patients with subfoveal CNV in PM at 12 (RD=0.20; 95% CI 0.03, 0.36), but not at 24 months. The effectiveness of PDT-V in patients with subfoveal CNV secondary to angioid streaks, ocular histoplasmosis syndrome, polypoidal choroidal vasculopathy, multifocal choroiditis and panuveitis, and due to idiopathic causes was uncertain as evidence was only available from case series. CONCLUSIONS: PDT-V reduces the rate of visual acuity loss in patients with predominantly classic subfoveal CNV secondary to AMD. The effectiveness of this therapy in other indications is difficult to assess due to the transient or delayed nature of treatment benefit or no comparator groups.
Publication Types:
Keywords:
- 1-phenyl-3,3-dimethyltriazene
- Angioid Streaks
- Case-Control Studies
- Choroidal Neovascularization
- Histoplasmosis
- Humans
- Macular Degeneration
- Myopia
- Photochemotherapy
- Porphyrins
- Triazenes
- verteporfin
- hsrmtgs
UI: 103140898
From Meeting Abstracts